152 related articles for article (PubMed ID: 38277741)
21. Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases.
Coati I; Lotz G; Fanelli GN; Brignola S; Lanza C; Cappellesso R; Pellino A; Pucciarelli S; Spolverato G; Guzzardo V; Munari G; Zaninotto G; Scarpa M; Mastracci L; Farinati F; Realdon S; Pilati P; Lonardi S; Valeri N; Rugge M; Kiss A; Loupakis F; Fassan M
Br J Cancer; 2019 Jul; 121(3):257-263. PubMed ID: 31235864
[TBL] [Abstract][Full Text] [Related]
22. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer.
Kubota Y; Shitara K
Ther Adv Med Oncol; 2024; 16():17588359231217967. PubMed ID: 38188462
[TBL] [Abstract][Full Text] [Related]
23. State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies.
Rogers JE; Ajani JA
Curr Opin Oncol; 2024 Jul; 36(4):308-312. PubMed ID: 38726797
[TBL] [Abstract][Full Text] [Related]
24. Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination.
Ogawa H; Abe H; Yagi K; Seto Y; Ushiku T
Gastric Cancer; 2024 Jul; 27(4):802-810. PubMed ID: 38724721
[TBL] [Abstract][Full Text] [Related]
25. Anti-Claudin Treatments in Gastroesophageal Adenocarcinoma: Mainstream and Upcoming Strategies.
Grizzi G; Venetis K; Denaro N; Bonomi M; Celotti A; Pagkali A; Hahne JC; Tomasello G; Petrelli F; Fusco N; Ghidini M
J Clin Med; 2023 Apr; 12(8):. PubMed ID: 37109309
[TBL] [Abstract][Full Text] [Related]
26. Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: A comparative study with tissue specimens.
Dai J; Zheng H; Jin J; Cheng Y; Xu H
Cancer Cytopathol; 2023 Jun; 131(6):365-372. PubMed ID: 36793190
[TBL] [Abstract][Full Text] [Related]
27. Claudin 18.2 as a New Biomarker in Gastric Cancer-What Should We Know?
Mathias-Machado MC; de Jesus VHF; Jácome A; Donadio MD; Aruquipa MPS; Fogacci J; Cunha RG; da Silva LM; Peixoto RD
Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339430
[TBL] [Abstract][Full Text] [Related]
28. Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma.
Shitara K; Kawazoe A; Hirakawa A; Nakanishi Y; Furuki S; Fukuda M; Ueno Y; Raizer J; Arozullah A
Cancer Sci; 2023 Apr; 114(4):1606-1615. PubMed ID: 36478334
[TBL] [Abstract][Full Text] [Related]
29. miR-1303 targets claudin-18 gene to modulate proliferation and invasion of gastric cancer cells.
Zhang SJ; Feng JF; Wang L; Guo W; Du YW; Ming L; Zhao GQ
Dig Dis Sci; 2014 Aug; 59(8):1754-63. PubMed ID: 24647998
[TBL] [Abstract][Full Text] [Related]
30. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
Jia K; Chen Y; Sun Y; Hu Y; Jiao L; Ma J; Yuan J; Qi C; Li Y; Gong J; Gao J; Zhang X; Li J; Zhang C; Shen L
BMC Med; 2022 Jul; 20(1):223. PubMed ID: 35811317
[TBL] [Abstract][Full Text] [Related]
31. Clinical Implications of Claudin18.2 Expression in Patients With Gastric Cancer.
Baek JH; Park DJ; Kim GY; Cheon J; Kang BW; Cha HJ; Kim JG
Anticancer Res; 2019 Dec; 39(12):6973-6979. PubMed ID: 31810969
[TBL] [Abstract][Full Text] [Related]
32. Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression.
Liu S; Zhang Z; Jiang L; Zhang M; Zhang C; Shen L
Cell Commun Signal; 2024 Jan; 22(1):27. PubMed ID: 38200591
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of claudin 18.2 expression in gastric adenocarcinoma.
Kayikcioglu E; Yüceer RO; Cetin B; Yüceer K; Karahan N
World J Gastrointest Oncol; 2023 Feb; 15(2):343-351. PubMed ID: 36908327
[TBL] [Abstract][Full Text] [Related]
34. Jianpi Yangzheng decoction suppresses gastric cancer progression via modulating the miR-448/CLDN18.2 mediated YAP/TAZ signaling.
Xu X; Li Y; Zhang R; Chen X; Shen J; Yuan M; Chen Y; Chen M; Liu S; Wu J; Sun Q
J Ethnopharmacol; 2023 Jul; 311():116450. PubMed ID: 37023839
[TBL] [Abstract][Full Text] [Related]
35. Analysis of the expression and genetic alteration of CLDN18 in gastric cancer.
Li J; Zhang Y; Hu D; Gong T; Xu R; Gao J
Aging (Albany NY); 2020 Jul; 12(14):14271-14284. PubMed ID: 32668412
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma.
Huang Y; You M; Wu Q; Chen R
Front Pharmacol; 2023; 14():1238009. PubMed ID: 37719841
[No Abstract] [Full Text] [Related]
37. Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody.
Bähr-Mahmud H; Ellinghaus U; Stadler CR; Fischer L; Lindemann C; Chaturvedi A; Diekmann J; Wöll S; Biermann I; Hebich B; Scharf C; Siefke M; Roth AS; Rao M; Brettschneider K; Ewen EM; Şahin U; Türeci Ö
Oncoimmunology; 2023; 12(1):2255041. PubMed ID: 37860278
[TBL] [Abstract][Full Text] [Related]
38. Claudins and Gastric Cancer: An Overview.
Hashimoto I; Oshima T
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053454
[TBL] [Abstract][Full Text] [Related]
39. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients.
Zhang Z; Liu X; Zhou L; Zhang M; Liang Z
Histol Histopathol; 2022 Oct; 37(10):1031-1040. PubMed ID: 35656795
[TBL] [Abstract][Full Text] [Related]
40. Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary.
Shitara K; Shah MA; Lordick F; Bang YJ; Ilson D; Cutsem EV; Enzinger P; Kim SS; Klempner SJ; Moran D; Park JW; Bhattacharya P; Ajani JA; Xu RH
Future Oncol; 2024 May; ():1-17. PubMed ID: 38861294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
